This or the causality of the observed mutations in DLBCL and multiple myeloma need further investigation by future screening studies of additional patients and functional studies of ACTB or ACTG1 mutants in appropriate models or patient material. This evidence concerns the gene ACTG1 and diffuse large B-cell lymphoma.